Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL7851452 | 0.90 | OPRM1 (0.48) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| SCHEMBL780308 | 0.88 | NPFFR1 (0.49) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| SCHEMBL781667 | 0.87 | OPRM1 (0.55) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| Hydrochloric Acid SCHEMBL11563478 | 0.86 | OPRM1 (0.54) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| SCHEMBL11562772 | 0.81 | OPRM1 (0.54) | OPRM1SLC22A1ABCB1OPRD1 | |
| SCHEMBL800532 | 0.80 | OPRM1 (0.50) | OPRM1SLC22A1ABCB1OPRD1 | |
| SCHEMBL11568939 | 0.79 | OPRM1 (0.54) | OPRM1SLC22A1ABCB1SMN1; SMN2OPRD1 | |
| SCHEMBL16440623 | 0.78 | CA12 (0.61) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| SCHEMBL15866340 | 0.77 | OPRM1 (0.46) | OPRM1SLC22A1ABCB1OPRD1 | |
| SCHEMBL801021 | 0.75 | OPRM1 (0.55) | OPRM1SLC22A1ABCB1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946433-B2 | Process for the preparation of sufentanil base and related compounds | MALLINCKRODT LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012037309-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | SNRPD1, SNRPD2, SNRPA1 | OPRM1 18/4885SLC22A1 2445/4885ABCB1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.